EEEric E. SchadtAug 11, 2025New paperautoPaperMilademetan in Advanced Solid Tumors with MDM2 Amplification and Wild-type TP53: Preclinical and Phase II Clinical Trial ResultsClinical Cancer Research · 2025 · Ecaterina E Dumbrava, Thomas E Stinchcombe, Mrinal Gounder et al.